Lupin Pharmaceuticals
India is among the top 10 pharmaceutical exporting countries with its share of the global market on the rise compared to the previous 5 years.
Lupin Ltd. is a leading pharmaceutical company from India and is amongst the top 10 generic companies in the world. It started its business in 1968 and over the years has become one of the largest pharmaceutical companies in India and the world. Its businesses include formulations, Active Pharmaceutical Ingredients (API), drug delivery systems and biotechnology. Lupin’s total revenue stood at Rs. 41,455 million (US$ 509.98 million) in the second quarter of FY 2022-23.
- Amongst the top 10 generic companies in the world
- 18 manufacturing sites
- Products sold in more than 100 countries
- Its consolidated income stood at Rs. 16,751 million (US$ 227.45 million) in FY21
| Year | Milestone |
|---|---|
| 2022 |
In October 2022, Lupin signed an agreement to acquire two inhalation brands from Sunovion Pharmaceuticals Inc. In June 2022, Lupin announced the launch of Lupin Diagnostics, its first Regional Reference Laboratory in Patna, Bihar. Lupin Limited (Lupin) announced that the United States Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA), Vigabatrin. |
| 2021 |
In September 2021, TB Alliance, a non-profit drug developer, granted Lupin Limited (Lupin) a non-exclusive licence to produce pretomanid, an anti-TB medicine that is part of the three-drug ‘BPal’ regimen. Lupin plans to market the anti-tuberculosis (TB) drug in more than 140 countries including the world's top TB-burdened regions. In June 2021, the company’s board of directors approved a proposal to enter the digital healthcare space in India. It incorporated Lupin Digital Health Ltd., a wholly owned subsidiary, to provide a digital therapeutics platform for medical practitioners and patients in the country. In May 2021, Lupin entered a royalty-free, non-exclusive licensing agreement with Eli Lilly and Company for expanding access to the COVID-19 drug, Baricitinib. The company will now manufacture and distribute the drug in India. In March 2021, Lupin and JIFFY.ai, an automation start-up, joined forces to expand Lupin’s automation initiatives. |
| 2020 |
Lupin launched ‘Tacrolimus’ capsules USP, 0.5 mg, 1 mg, and 5 mg, after its partner, Concord Biotech Limited (Concord), received an approval for ANDA (Abbreviated New Drug Application) from the United States Food and Drug Administration Lupin launched Favipiravir under the drug name ‘Covihalt’ for the treatment of patients with mild to moderate Covid-19 symptoms. This medicine is available at Rs. 49 (US$ 0.66)/ tablet in India. Lupin launched the generic version of Bausch Health's Apriso, used in the treatment of ulcerative colitis, in the US market |
| 2019 |
Lupin launched Adhero, a first-of-its-kind connected Smart Device in India to support treatment of Respiratory Disease Received approval for its propranolol Hydrochloride Extended-Release (ER) capsules from Health Canada Lupin’s subsidiary in South Africa declared commercial agreement with Creso Pharma Nagpur facility won ENR Global Best Project Award Launched Doxercalciferol Injection, 4 mcg/2 ml multidose vials, for the treatments of secondary hyperparathyroidism in adult patients with CKD on dialysis |
| 2017 |
Entered over the counter (OTC) market with launch of Softovac in India |
| 2016 |
Acquired US-based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. |
| 2010 |
Became fifth largest generic player in the US |
| 2004 |
Commenced US Brands Business with the launch of Suprax |
| 2002 |
More than 100 patent filings |
| 1993 |
Lupin Laboratories Ltd. and Lupin Chemicals Ltd. raise money through IPOs |
| 1989 |
Joint venture in Thailand and Lupin Chemicals (Thailand) Ltd was formed |
| 1980 |
Commissioned first Formulations plant and an R&D center at Aurangabad, Maharashtra |
| 1968 |
Commenced business |
Partners
